Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors

Baraibar-Argota, I. (Iosune)|||/items/7e21232f-3890-4d16-901d-006ef5420eb1; Martin-Romano, P. (Patricia)|||/items/d5da8b9c-e6c8-4e0a-9ab8-300dd23a5df2; Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09; Rodriguez-Ruiz, M.E. (María Esperanza)|||/items/bb89f8c4-6380-4de3-8dd0-877dbf28ef44; Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e; Resano, L. (Leyre)|||/items/31b6e030-b78a-4b56-93c2-7d811832e718; Ortega-Montes, A. (Ana)|||/items/99a6623e-27c7-4d74-9cf7-fe57e11c99bf; Ponz-Sarvise, M. (Mariano)|||/items/2439c580-068e-431b-a20d-bdeab1b7c3ad; Castañón-Álvarez, E. (Eduardo)|||/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7a

Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors

First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) afte...

ver descrição completa

Detalhes bibliográficos
Autores:	Baraibar-Argota, I. (Iosune)\|\|\|/items/7e21232f-3890-4d16-901d-006ef5420eb1, Martin-Romano, P. (Patricia)\|\|\|/items/d5da8b9c-e6c8-4e0a-9ab8-300dd23a5df2, Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)\|\|\|/items/35ac602c-f0ff-4664-bbd2-506afc96db09, Rodriguez-Ruiz, M.E. (María Esperanza)\|\|\|/items/bb89f8c4-6380-4de3-8dd0-877dbf28ef44, Melero, I. (Ignacio)\|\|\|/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e, Resano, L. (Leyre)\|\|\|/items/31b6e030-b78a-4b56-93c2-7d811832e718, Ortega-Montes, A. (Ana)\|\|\|/items/99a6623e-27c7-4d74-9cf7-fe57e11c99bf, Ponz-Sarvise, M. (Mariano)\|\|\|/items/2439c580-068e-431b-a20d-bdeab1b7c3ad, Castañón-Álvarez, E. (Eduardo)\|\|\|/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7a
Tipo de documento:	artigo
Data de publicação:	2018
País:	España
Recursos:	Universidad de Navarra
Repositório:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglês
OAI Identifier:	oai:dadun.unav.edu:10171/65316
Acesso em linha:	https://hdl.handle.net/10171/65316
Access Level:	Acceso aberto
Palavra-chave:	Progression free survival (PFS) Gastrointestinal cancers (GIC)

id	ES_fc1187b3224d5cd194e33d035bc4fb13
oai_identifier_str	oai:dadun.unav.edu:10171/65316
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumorsBaraibar-Argota, I. (Iosune)\|\|\|/items/7e21232f-3890-4d16-901d-006ef5420eb1Martin-Romano, P. (Patricia)\|\|\|/items/d5da8b9c-e6c8-4e0a-9ab8-300dd23a5df2Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)\|\|\|/items/35ac602c-f0ff-4664-bbd2-506afc96db09Rodriguez-Ruiz, M.E. (María Esperanza)\|\|\|/items/bb89f8c4-6380-4de3-8dd0-877dbf28ef44Melero, I. (Ignacio)\|\|\|/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4eResano, L. (Leyre)\|\|\|/items/31b6e030-b78a-4b56-93c2-7d811832e718Ortega-Montes, A. (Ana)\|\|\|/items/99a6623e-27c7-4d74-9cf7-fe57e11c99bfPonz-Sarvise, M. (Mariano)\|\|\|/items/2439c580-068e-431b-a20d-bdeab1b7c3adCastañón-Álvarez, E. (Eduardo)\|\|\|/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7aProgression free survival (PFS)Gastrointestinal cancers (GIC)First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and PFS. We have studied TGR and PFS before and after participation in phase I IT trials.ElsevierDadun. Depósito Académico Digital Universidad de Navarra20232023-02-0820182018-01-0120182018-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/65316reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/653162026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
title	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
spellingShingle	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors Baraibar-Argota, I. (Iosune)\|\|\|/items/7e21232f-3890-4d16-901d-006ef5420eb1 Progression free survival (PFS) Gastrointestinal cancers (GIC)
title_short	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
title_full	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
title_fullStr	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
title_full_unstemmed	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
title_sort	Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
dc.creator.none.fl_str_mv	Baraibar-Argota, I. (Iosune)\|\|\|/items/7e21232f-3890-4d16-901d-006ef5420eb1 Martin-Romano, P. (Patricia)\|\|\|/items/d5da8b9c-e6c8-4e0a-9ab8-300dd23a5df2 Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)\|\|\|/items/35ac602c-f0ff-4664-bbd2-506afc96db09 Rodriguez-Ruiz, M.E. (María Esperanza)\|\|\|/items/bb89f8c4-6380-4de3-8dd0-877dbf28ef44 Melero, I. (Ignacio)\|\|\|/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e Resano, L. (Leyre)\|\|\|/items/31b6e030-b78a-4b56-93c2-7d811832e718 Ortega-Montes, A. (Ana)\|\|\|/items/99a6623e-27c7-4d74-9cf7-fe57e11c99bf Ponz-Sarvise, M. (Mariano)\|\|\|/items/2439c580-068e-431b-a20d-bdeab1b7c3ad Castañón-Álvarez, E. (Eduardo)\|\|\|/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7a
author	Baraibar-Argota, I. (Iosune)\|\|\|/items/7e21232f-3890-4d16-901d-006ef5420eb1
author_facet	Baraibar-Argota, I. (Iosune)\|\|\|/items/7e21232f-3890-4d16-901d-006ef5420eb1 Martin-Romano, P. (Patricia)\|\|\|/items/d5da8b9c-e6c8-4e0a-9ab8-300dd23a5df2 Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)\|\|\|/items/35ac602c-f0ff-4664-bbd2-506afc96db09 Rodriguez-Ruiz, M.E. (María Esperanza)\|\|\|/items/bb89f8c4-6380-4de3-8dd0-877dbf28ef44 Melero, I. (Ignacio)\|\|\|/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e Resano, L. (Leyre)\|\|\|/items/31b6e030-b78a-4b56-93c2-7d811832e718 Ortega-Montes, A. (Ana)\|\|\|/items/99a6623e-27c7-4d74-9cf7-fe57e11c99bf Ponz-Sarvise, M. (Mariano)\|\|\|/items/2439c580-068e-431b-a20d-bdeab1b7c3ad Castañón-Álvarez, E. (Eduardo)\|\|\|/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7a
author_role	author
author2	Martin-Romano, P. (Patricia)\|\|\|/items/d5da8b9c-e6c8-4e0a-9ab8-300dd23a5df2 Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)\|\|\|/items/35ac602c-f0ff-4664-bbd2-506afc96db09 Rodriguez-Ruiz, M.E. (María Esperanza)\|\|\|/items/bb89f8c4-6380-4de3-8dd0-877dbf28ef44 Melero, I. (Ignacio)\|\|\|/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e Resano, L. (Leyre)\|\|\|/items/31b6e030-b78a-4b56-93c2-7d811832e718 Ortega-Montes, A. (Ana)\|\|\|/items/99a6623e-27c7-4d74-9cf7-fe57e11c99bf Ponz-Sarvise, M. (Mariano)\|\|\|/items/2439c580-068e-431b-a20d-bdeab1b7c3ad Castañón-Álvarez, E. (Eduardo)\|\|\|/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7a
author2_role	author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Progression free survival (PFS) Gastrointestinal cancers (GIC)
topic	Progression free survival (PFS) Gastrointestinal cancers (GIC)
description	First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and PFS. We have studied TGR and PFS before and after participation in phase I IT trials.
publishDate	2018
dc.date.none.fl_str_mv	2018 2018-01-01 2018 2018-01-01 2023 2023-02-08
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/65316
url	https://hdl.handle.net/10171/65316
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869425387631542272
score	15.300719

Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors

Registros relacionados